| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/350259/2013 (14.06.13) |
| Publication Date | 14/06/2013 |
| Content Type | News |
|
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC), in June 2013, recommended a series of measures to address safety concerns with codeine-containing medicines when used for the management of pain in children. This followed the PRAC’s review of reports of children who developed serious adverse effects or died after taking codeine for pain relief. Most of the cases occurred after surgical removal of the tonsils or adenoids for obstructive sleep apnoea (frequent interruption of breathing during sleep). Codeine is an opioid that is authorised as painkiller in adults and children. It is converted into morphine in the patient’s body. |
|
| Source Link | http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001813.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Geography, Health |
| Countries / Regions | Europe |
